SCHEMBL30745814

SCHEMBL30745814

COc1cc(OC)c(Cl)c(N(C(=O)NCc2cc(N(C(=O)OC(C)(C)C)c3ccc(N4CCC(N(C)C5CC5)CC4)cc3[N+](=O)[O-])ncn2)C(=O)OC(C)(C)C)c1Cl

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FGFR1 P11362 10/20 0.40
▸ FGFR4 P22455 8/20 0.40
▸ FGFR3 P22607 7/20 0.40
▸ FGFR2 P21802 6/20 0.40
▸ PLK1 P53350 6/20 0.35
▸ JAK2 O60674 2/20 0.34
▸ ABL1 P00519 2/20 0.34
▸ INSR P06213 2/20 0.34
▸ LCK P06239 2/20 0.34
▸ FYN P06241 2/20 0.34
▸ YES1 P07947 2/20 0.34
▸ LYN P07948 2/20 0.34
▸ RET P07949 2/20 0.34
▸ MET P08581 2/20 0.34
▸ ROS1 P08922 2/20 0.34
▸ KIT P10721 2/20 0.34
▸ SRC P12931 2/20 0.34
▸ BRAF P15056 2/20 0.34
▸ PDGFRA P16234 2/20 0.34
▸ FLT1 P17948 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20836806 1.00 FGFR1 (0.40) FGFR1FGFR4FGFR3FGFR2PLK1
SCHEMBL20995387 0.97 FGFR1 (0.39) FGFR1FGFR4FGFR3FGFR2PLK1
SCHEMBL28586199 0.89 FGFR1 (0.43) FGFR1FGFR4FGFR3FGFR2PLK1
SCHEMBL20836827 0.89 FGFR1 (0.39) FGFR1FGFR4FGFR3FGFR2PLK1
SCHEMBL19633409 0.88 FGFR1 (0.42) FGFR1FGFR4FGFR3FGFR2PLK1
SCHEMBL20836791 0.87 FGFR1 (0.48) FGFR1FGFR4FGFR3FGFR2PLK1
SCHEMBL20836798 0.87 FGFR1 (0.41) FGFR1FGFR4FGFR3FGFR2JAK2
SCHEMBL20836829 0.86 FGFR1 (0.42) FGFR1FGFR4FGFR3FGFR2PLK1
SCHEMBL19633355 0.84 FGFR1 (0.42) FGFR1FGFR4FGFR3FGFR2PLK1
SCHEMBL20836824 0.83 FGFR1 (0.55) FGFR1FGFR4FGFR3FGFR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12358898-B2 Pyrimidine derivative, method for preparing same and use thereof in medicine ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) 2025-07-15 — — US disclosed
US-20240018130-A1 Pyrimidine Derivative, Method For Preparing Same And Use Thereof In Medicine ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) 2024-01-18 — — US disclosed
US-11827625-B2 Pyrimidine derivative, method for preparing same and use thereof in medicine ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. 2023-11-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11827625-B2 Pyrimidine derivative, method for preparing same and use thereof in medicine FGFR4, FGFR1, FGFR2 FGFR1 2/4885FGFR4 1/4885FGFR3 4/4885
US-12358898-B2 Pyrimidine derivative, method for preparing same and use thereof in medicine FGFR4, FGFR1, FGFR2 FGFR1 2/4885FGFR4 1/4885FGFR3 4/4885
US-20240018130-A1 Pyrimidine Derivative, Method For Preparing Same And Use Thereof In Medicine FGFR4, FGFR1, FGFR2 FGFR1 2/4885FGFR4 1/4885FGFR3 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback